A Phase 1 interventional study of LY2940680 Capsule(s) (Reference) and LY2940680 Tablet (Test) in Healthy Participants, sponsored by Eli Lilly and Company. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-10-21.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study involves 2 parts, Part A and Part B. The purpose of Part A is to evaluate the safety and side effects of LY2940680 in healthy participants. Part A will involve two groups of participants, each taking up to two single doses of LY2940680 at different dose levels. There is a minimum 14 day washout period between each of the participant's doses. The purpose of Part B is to study how much of the study drug, in capsule or tablet form, gets into the bloodstream and how long the body takes to get rid of it. In addition, the effect of food and a proton pump inhibitor (PPI) on LY2940680 will be studied. Part B will involve one group of participants who will take four single doses of 100 milligrams (mg) LY2940680. There is a minimum 7 day washout period between doses. Participants may only enroll in one part. Screening is required within 28 days prior to the start of the study.
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single escalating dose (50 mg up to 400 mg) of LY2940680 given once orally in up to 2 of 2 study periods
Drug: LY2940680 Capsule(s) (Reference)
Placebo given once orally in up to 1 of 2 study periods
Drug: Placebo Capsule(s)
100 mg LY2940680 given once orally as a capsule (reference formulation) in fasted state in 1 of 4 study periods
Drug: LY2940680 Capsule(s) (Reference)
100 mg LY2940680 given once orally as a tablet (test formulation) in fasted state in 1 of 4 study periods
Drug: LY2940680 Tablet (Test)
100 mg LY2940680 given once orally as a tablet (test formulation) in fed state following a standardized, high-fat breakfast in 1 of 4 study periods
Drug: LY2940680 Tablet (Test)
30 mg lansoprazole (PPI) given orally once daily for 7 days. One hour after last dose, 100 mg LY2940680 given orally once as a tablet (test formulation) in fasted state in 1 of 4 study periods
Drug: LY2940680 Tablet (Test) · Drug: Lansoprazole
Administered orally as a capsule(s)
Administered orally as a tablet
Administered orally as a capsule
Administered orally as a capsule(s)
Number of Participants With 1 or More Adverse Events (AEs) or Any Serious AEs
Data presented are the number of participants with AEs or any serious AEs (SAEs) regardless of causality. A summary of non-serious AEs is located in the Reported Adverse Events section.
Time frame: Baseline through study completion (up to 4 weeks in Part A and 8 weeks in Part B)
Part B: Pharmacokinetics: Maximum Observed Concentrations (Cmax) of LY2940680 Test and Reference Formulation
The Cmax of 100-milligram (mg) LY2940680 capsule (reference formulation) and 100-mg LY2940680 tablet (test formulation) in fasted and fed state, and with lansoprazole during Part B of the study.
Time frame: Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, and 96 hours after administration of study drug
Part A: Pharmacokinetics: Maximum Observed Drug Concentration (Cmax)
The Cmax of LY2940680 during Part A of the study was reported.
Time frame: Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, and 120 hours after administration of study drug
Part A: Pharmacokinetics: Time to Maximum Observed Drug Concentration (Tmax)
Part A: Pharmacokinetics: Time to Maximum Observed Drug Concentration (tmax)
Time frame: Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, and 120 hours after administration of study drug
Part B: Pharmacokinetics: Time to Maximum Observed Drug Concentration (Tmax)
Part B: Pharmacokinetics: Time to Maximum Observed Drug Concentration (tmax)
Time frame: Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72 and 96 hours after administration of study drug
Part A: Pharmacokinetics: Area Under the Curve From Time Zero to Time T, Where T is the Last Time Point With a Measurable Concentration [AUC(0-tlast)]
Part A: Pharmacokinetics: Area Under the Curve from Time Zero to Time T, where T is the Last Time Point with a Measurable Concentration \[AUC(0-tlast)\]
Time frame: Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, and 120 hours after administration of study drug
Part B: Pharmacokinetics: Area Under the Curve From Time Zero to Time T, Where T is the Last Time Point With a Measurable Concentration [AUC(0-tlast)]
Part B: Pharmacokinetics: Area Under the Curve from Time Zero to Time T, where T is the Last Time Point with a Measurable Concentration \[AUC(0-tlast)\]
Time frame: Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72 and 96 hours after administration of study drug
Part A: Pharmacokinetics: Area Under the Curve From Time Zero to Infinity [AUC(0-∞)]
Part A: Pharmacokinetics: Area Under the Curve From Time Zero to Infinity \[AUC(0-∞)\]
Time frame: Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, and 120 hours after administration of study drug
Part B: Pharmacokinetics: Area Under the Curve From Time Zero to Infinity [AUC(0-∞)]
Part B: Pharmacokinetics: Area Under the Curve From Time Zero to Infinity \[AUC(0-∞)\]
Time frame: Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72 and 96 hours after administration of study drug
| Milestone | Part A, Cohort 1, Sequence 1 | Part A, Cohort 1, Sequence 2 | Part A, Cohort 1, Sequence 3 | Part A, Cohort 2, Sequence 4 | Part A, Cohort 2, Sequence 5 | Part A, Cohort 2, Sequence 6 | Part B, Cohort 3, Sequence 1 | Part B, Cohort 3, Sequence 2 |
|---|---|---|---|---|---|---|---|---|
| Started | 4 | 2 | 2 | 3 | 3 | 2 | 7 | 7 |
| Completed | 4 | 2 | 2 | 3 | 3 | 2 | 7 | 7 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Part A, Cohort 1, Sequence 1 | Part A, Cohort 1, Sequence 2 | Part A, Cohort 1, Sequence 3 | Part A, Cohort 2, Sequence 4 | Part A, Cohort 2, Sequence 5 | Part A, Cohort 2, Sequence 6 | Part B, Cohort 3, Sequence 1 | Part B, Cohort 3, Sequence 2 |
|---|---|---|---|---|---|---|---|---|
| Started | 4 | 2 | 2 | 3 | 3 | 2 | 7 | 7 |
| Completed | 4 | 2 | 2 | 3 | 3 | 2 | 7 | 7 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Part A, Cohort 1, Sequence 1 | Part A, Cohort 1, Sequence 2 | Part A, Cohort 1, Sequence 3 | Part A, Cohort 2, Sequence 4 | Part A, Cohort 2, Sequence 5 | Part A, Cohort 2, Sequence 6 | Part B, Cohort 3, Sequence 1 | Part B, Cohort 3, Sequence 2 |
|---|---|---|---|---|---|---|---|---|
| Started | 4 | 2 | 2 | 3 | 3 | 2 | 7 | 7 |
| Completed | 4 | 2 | 2 | 3 | 3 | 2 | 7 | 7 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Part A, Cohort 1, Sequence 1 | Part A, Cohort 1, Sequence 2 | Part A, Cohort 1, Sequence 3 | Part A, Cohort 2, Sequence 4 | Part A, Cohort 2, Sequence 5 | Part A, Cohort 2, Sequence 6 | Part B, Cohort 3, Sequence 1 | Part B, Cohort 3, Sequence 2 |
|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 7 | 7 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 6 | 6 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Milestone | Part A, Cohort 1, Sequence 1 | Part A, Cohort 1, Sequence 2 | Part A, Cohort 1, Sequence 3 | Part A, Cohort 2, Sequence 4 | Part A, Cohort 2, Sequence 5 | Part A, Cohort 2, Sequence 6 | Part B, Cohort 3, Sequence 1 | Part B, Cohort 3, Sequence 2 |
|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 6 | 6 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 6 | 6 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Part A, Cohort 1, Sequence 1 | Part A, Cohort 1, Sequence 2 | Part A, Cohort 1, Sequence 3 | Part A, Cohort 2, Sequence 4 | Part A, Cohort 2, Sequence 5 | Part A, Cohort 2, Sequence 6 | Part B, Cohort 3, Sequence 1 | Part B, Cohort 3, Sequence 2 |
|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 6 | 6 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 6 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Milestone | Part A, Cohort 1, Sequence 1 | Part A, Cohort 1, Sequence 2 | Part A, Cohort 1, Sequence 3 | Part A, Cohort 2, Sequence 4 | Part A, Cohort 2, Sequence 5 | Part A, Cohort 2, Sequence 6 | Part B, Cohort 3, Sequence 1 | Part B, Cohort 3, Sequence 2 |
|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 6 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 5 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
Data presented are the number of participants with AEs or any serious AEs (SAEs) regardless of causality. A summary of non-serious AEs is located in the Reported Adverse Events section.
| Participants | Placebo Capsule (Fasted) | 50-mg LY2940680 Capsule (Fasted) | 100-mg LY2940680 Capsule (Fasted) Part A | 100-mg LY2940680 Capsule (Fasted) Part B | 100-mg LY2940680 Tablet (Fasted) | 100-mg LY2940680 Tablet Plus 30-mg Lansoprazole (Fasted) | 100-mg LY2940680 Tablet (Fed) | 200-mg LY2940680 Capsule (Fasted) | 400-mg LY2940680 Capsule (Fasted) |
|---|---|---|---|---|---|---|---|---|---|
| Adverse Events (AEs) | 2 | 3 | 4 | 6 | 5 | 3 | 5 | 3 | 3 |
| Serious Adverse Events (SAEs) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
The Cmax of 100-milligram (mg) LY2940680 capsule (reference formulation) and 100-mg LY2940680 tablet (test formulation) in fasted and fed state, and with lansoprazole during Part B of the study.
| nanograms per milliliter (ng/mL) | 100-mg LY2940680 Capsule (Fasted) | 100-mg LY2940680 Tablet (Fasted) | 100-mg LY2940680 Tablet (Fed) | 100-mg LY2940680 Tablet Plus 30-mg Lansoprazole (Fasted) |
|---|---|---|---|---|
| Part B: Pharmacokinetics: Maximum Observed Concentrations (Cmax) of LY2940680 Test and Reference Formulation | 879 ± 49.3 | 1170 ± 22.4 | 776 ± 26.3 | 1290 ± 47.9 |
The Cmax of LY2940680 during Part A of the study was reported.
| nanograms per milliliter (ng/mL) | 50-mg LY2940680 Capsule (Fasted) | 100-mg LY2940680 Capsule (Fasted) | 200-mg LY2940680 Capsule (Fasted) | 400-mg LY2940680 Capsule (Fasted) |
|---|---|---|---|---|
| Part A: Pharmacokinetics: Maximum Observed Drug Concentration (Cmax) | 622 ± 25.3 | 661 ± 68.3 | 1740 ± 15.6 | 3360 ± 32.8 |
Part A: Pharmacokinetics: Time to Maximum Observed Drug Concentration (tmax)
| hours (h) | 50-mg LY2940680 Capsule (Fasted) | 100-mg LY2940680 Capsule (Fasted) | 200-mg LY2940680 Capsule (Fasted) | 400-mg LY2940680 Capsule (Fasted) |
|---|---|---|---|---|
| Part A: Pharmacokinetics: Time to Maximum Observed Drug Concentration (Tmax) | 1.5 (0.92 to 3.0) | 2 (2.0 to 4.03) | 2 (1.0 to 2.0) | 2 (1.0 to 3.0) |
Part B: Pharmacokinetics: Time to Maximum Observed Drug Concentration (tmax)
| hours (h) | 100-mg LY2940680 Capsule (Fasted) | 100-mg LY2940680 Tablet (Fasted) | 100-mg LY2940680 Tablet (Fed) | 100-mg LY2940680 Tablet (Fasted) PPI |
|---|---|---|---|---|
| Part B: Pharmacokinetics: Time to Maximum Observed Drug Concentration (Tmax) | 1 (1 to 4) | 1.5 (1 to 4) | 3 (2 to 8) | 1 (1 to 3) |
Part A: Pharmacokinetics: Area Under the Curve from Time Zero to Time T, where T is the Last Time Point with a Measurable Concentration \[AUC(0-tlast)\]
| nanograms*hours per milliliter (ng*h/mL) | 50-mg LY2940680 Capsule (Fasted) | 100-mg LY2940680 Capsule (Fasted) | 200-mg LY2940680 Capsule (Fasted) | 400-mg LY2940680 Capsule (Fasted) |
|---|---|---|---|---|
| Part A: Pharmacokinetics: Area Under the Curve From Time Zero to Time T, Where T is the Last Time Point With a Measurable Concentration [AUC(0-tlast)] | 5300 ± 27.5 | 9440 ± 53.9 | 22800 ± 21.2 | 49300 ± 27.9 |
Part B: Pharmacokinetics: Area Under the Curve from Time Zero to Time T, where T is the Last Time Point with a Measurable Concentration \[AUC(0-tlast)\]
| nanograms*hours per milliliter (ng*h/mL) | 100-mg LY2940680 Capsule (Fasted) | 100-mg LY2940680 Tablet (Fasted) | 100-mg LY2940680 Tablet (Fed) | 100-mg LY2940680 Tablet (Fasted) PPI |
|---|---|---|---|---|
| Part B: Pharmacokinetics: Area Under the Curve From Time Zero to Time T, Where T is the Last Time Point With a Measurable Concentration [AUC(0-tlast)] | 9390 ± 41.1 | 10300 ± 39.9 | 11200 ± 37.2 | 9980 ± 50.1 |
Part A: Pharmacokinetics: Area Under the Curve From Time Zero to Infinity \[AUC(0-∞)\]
| nanograms*hours per milliliter (ng*h/mL) | 50-mg LY2940680 Capsule (Fasted) | 100-mg LY2940680 Capsule (Fasted) | 200-mg LY2940680 Capsule (Fasted) | 400-mg LY2940680 Capsule (Fasted) |
|---|---|---|---|---|
| Part A: Pharmacokinetics: Area Under the Curve From Time Zero to Infinity [AUC(0-∞)] | 5340 ± 27.4 | 9530 ± 54.0 | 23000 ± 21.6 | 49800 ± 28.3 |
Part B: Pharmacokinetics: Area Under the Curve From Time Zero to Infinity \[AUC(0-∞)\]
| nanograms*hours per milliliter (ng*h/mL) | 100-mg LY2940680 Capsule (Fasted) | 100-mg LY2940680 Tablet (Fasted) | 100-mg LY2940680 Tablet (Fed) | 100-mg LY2940680 Tablet (Fasted) PPI |
|---|---|---|---|---|
| Part B: Pharmacokinetics: Area Under the Curve From Time Zero to Infinity [AUC(0-∞)] | 9460 ± 41.3 | 10300 ± 40.1 | 11300 ± 37.3 | 10000 ± 50.1 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo Capsule (Fasted) | — | 0/9 (0%) | 2/9 (22.2%) |
| 50-mg LY2940680 Capsule (Fasted) | — | 0/6 (0%) | 3/6 (50%) |
| 100-mg LY2940680 Capsule (Fasted) Part A or Part B | — | 0/20 (0%) | 10/20 (50%) |
| 100 mg LY2940680 Tablet (Fasted) | — | 0/14 (0%) | 5/14 (35.7%) |
| 100-mg LY2940680 Tablet Plus 30-mg Lansoprazole (Fasted) | — | 0/11 (0%) | 3/11 (27.3%) |
| 100-mg LY2940680 Tablet (Fed) | — | 0/12 (0%) | 5/12 (41.7%) |
| 200-mg LY2940680 Capsule (Fasted) | — | 0/6 (0%) | 3/6 (50%) |
| 400-mg LY2940680 Capsule (Fasted) | — | 0/5 (0%) | 3/5 (60%) |
| Event | Placebo Capsule (Fasted) | 50-mg LY2940680 Capsule (Fasted) | 100-mg LY2940680 Capsule (Fasted) Part A or Part B | 100 mg LY2940680 Tablet (Fasted) | 100-mg LY2940680 Tablet Plus 30-mg Lansoprazole (Fasted) | 100-mg LY2940680 Tablet (Fed) | 200-mg LY2940680 Capsule (Fasted) | 400-mg LY2940680 Capsule (Fasted) |
|---|---|---|---|---|---|---|---|---|
| HeadacheNervous system disorders | 2/9 | 1/6 | 6/20 | 3/14 | 0/11 | 3/12 | 3/6 | 1/5 |
| Muscle spasmsMusculoskeletal and connective tissue disorders | 0/9 | 0/6 | 0/20 | 0/14 | 0/11 | 0/12 | 0/6 | 2/5 |
| NauseaGastrointestinal disorders | 1/9 | 1/6 | 2/20 | 0/14 | 0/11 | 1/12 | 2/6 | 0/5 |
| Nasal congestionRespiratory, thoracic and mediastinal disorders | 0/9 | 1/6 | 1/20 | 0/14 | 0/11 | 0/12 | 0/6 | 1/5 |
| ParaesthesiaNervous system disorders | 0/9 | 0/6 | 0/20 | 0/14 | 0/11 | 0/12 | 1/6 | 0/5 |
| FlushingVascular disorders | 0/9 | 1/6 | 0/20 | 0/14 | 0/11 | 0/12 | 0/6 | 0/5 |
| DizzinessNervous system disorders | 0/9 | 0/6 | 3/20 | 0/14 | 0/11 | 0/12 | 0/6 | 0/5 |
| VomitingGastrointestinal disorders | 0/9 | 0/6 | 2/20 | 0/14 | 1/11 | 1/12 | 0/6 | 0/5 |
| Facial painGeneral disorders | 0/9 | 0/6 | 0/20 | 0/14 | 1/11 | 0/12 | 0/6 | 0/5 |
| PainGeneral disorders | 0/9 | 0/6 | 0/20 | 0/14 | 1/11 | 0/12 | 0/6 | 0/5 |
All randomized participants in Part A and B of the study.
| Age, Categorical(Participants) | Part A, Cohort 1, Sequence 1 | Part A, Cohort 1, Sequence 2 | Part A, Cohort 1, Sequence 3 | Part A, Cohort 2, Sequence 4 | Part A, Cohort 2, Sequence 5 | Part A, Cohort 2, Sequence 6 | Part B, Cohort 3, Sequence 1 | Part B, Cohort 3, Sequence 2 | Total |
|---|---|---|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 4 | 2 | 2 | 3 | 3 | 2 | 7 | 7 | 30 |
| >=65 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Part A, Cohort 1, Sequence 1 | Part A, Cohort 1, Sequence 2 | Part A, Cohort 1, Sequence 3 | Part A, Cohort 2, Sequence 4 | Part A, Cohort 2, Sequence 5 | Part A, Cohort 2, Sequence 6 | Part B, Cohort 3, Sequence 1 | Part B, Cohort 3, Sequence 2 | Total |
|---|---|---|---|---|---|---|---|---|---|
| Female | 4 | 2 | 2 | 2 | 3 | 1 | 7 | 7 | 28 |
| Male | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 2 |
| Ethnicity (NIH/OMB)(Participants) | Part A, Cohort 1, Sequence 1 | Part A, Cohort 1, Sequence 2 | Part A, Cohort 1, Sequence 3 | Part A, Cohort 2, Sequence 4 | Part A, Cohort 2, Sequence 5 | Part A, Cohort 2, Sequence 6 | Part B, Cohort 3, Sequence 1 | Part B, Cohort 3, Sequence 2 | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 1 | 0 | 1 | 4 | 4 | 10 |
| Not Hispanic or Latino | 4 | 2 | 2 | 2 | 3 | 1 | 3 | 3 | 20 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Part A, Cohort 1, Sequence 1 | Part A, Cohort 1, Sequence 2 | Part A, Cohort 1, Sequence 3 | Part A, Cohort 2, Sequence 4 | Part A, Cohort 2, Sequence 5 | Part A, Cohort 2, Sequence 6 | Part B, Cohort 3, Sequence 1 | Part B, Cohort 3, Sequence 2 | Total |
|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 |
| Black or African American | 0 | 1 | 0 | 0 | 2 | 0 | 2 | 2 | 7 |
| White | 3 | 1 | 2 | 2 | 1 | 2 | 5 | 5 | 21 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Part A, Cohort 1, Sequence 1 | Part A, Cohort 1, Sequence 2 | Part A, Cohort 1, Sequence 3 | Part A, Cohort 2, Sequence 4 | Part A, Cohort 2, Sequence 5 | Part A, Cohort 2, Sequence 6 | Part B, Cohort 3, Sequence 1 | Part B, Cohort 3, Sequence 2 | Total |
|---|---|---|---|---|---|---|---|---|---|
| United States | 4 | 2 | 2 | 3 | 3 | 2 | 7 | 7 | 30 |
Plan to share: No
No publications or documents are linked to this record.
The record gives a start of Sep 2012, a primary completion of Dec 2012 and a completion of Dec 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2019, 6 years 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: LY2940680